

Supplemental Table 1. Presence of all Elixhauser Comorbidity Index diagnoses among all study patients, and those with and without severe COVID

	All SLE Patients with COVID N=2,890	Severe COVID N=500	No severe COVID N=2,390	p-value
Baseline comorbidities,¹ N (%)				
AIDS/HIV	5 (0.2%)	3 (0.6%)	2 (0.1%)	0.039
Alcohol abuse	38 (1.3%)	13 (2.6%)	25 (1.0%)	0.006
Blood loss anemia	102 (3.5%)	25 (5.0%)	77 (3.2%)	0.050
Chronic pulmonary disease	436 (15.1%)	95 (19.0%)	341 (14.3%)	0.007
Coagulopathy	248 (8.6%)	75 (15.0%)	173 (7.2%)	<0.001
Congestive heart failure	187 (6.5%)	86 (17.2%)	101 (4.2%)	<0.001
Deficiency anemia	723 (25.0%)	206 (41.2%)	517 (21.6%)	<0.001
Depression	738 (25.5%)	153 (30.6%)	585 (24.5%)	0.004
Diabetes, complicated	297 (10.3%)	108 (21.6%)	189 (7.9%)	<0.001
Diabetes, uncomplicated	163 (5.6%)	46 (9.2%)	117 (4.9%)	<0.001
Drug abuse	155 (5.4%)	43 (8.6%)	112 (4.7%)	<0.001
Fluid and electrolyte disorders	480 (16.6%)	163 (32.6%)	317 (13.3%)	<0.001
Hypertension, complicated	400 (13.8%)	154 (30.8%)	246 (10.3%)	<0.001
Hypertension, uncomplicated	1,039 (36.0%)	198 (39.6%)	841 (35.2%)	0.062
Hypothyroidism	480 (16.6%)	78 (15.6%)	402 (16.8%)	0.505
Liver disease	162 (5.6%)	32 (6.4%)	130 (5.4%)	0.396
Lymphoma	34 (1.2%)	11 (2.2%)	23 (1.0%)	0.020
Metastatic cancer	13 (0.4%)	03 (0.6%)	10 (0.4%)	0.481
Non-paralysis neurological disorders	382 (13.2%)	102 (20.4%)	280 (11.7%)	<0.001
Obesity	955 (33.0%)	200 (40.0%)	755 (31.6%)	<0.001
Paralysis	54 (1.9%)	15 (3.0%)	39 (1.6%)	0.040
Peptic ulcer disease, excluding bleeding	43 (1.5%)	18 (3.6%)	25 (1.0%)	<0.001
Peripheral vascular disorders	185 (6.4%)	60 (12.0%)	125 (5.2%)	<0.001
Psychoses	240 (8.3%)	66 (13.2%)	174 (7.3%)	<0.001
Pulmonary circulation disorders	99 (3.4%)	34 (6.8%)	65 (2.7%)	<0.001
Renal failure	357 (12.4%)	148 (29.6%)	209 (8.7%)	<0.001
RA/collagen vascular diseases	2,602 (90.0%)	445 (89.0%)	2,157 (90.3%)	0.396
Solid tumor without metastasis	85 (2.9%)	14 (2.8%)	71 (3.0%)	0.837
Valvular disease	297 (10.3%)	86 (17.2%)	211 (8.8%)	<0.001
Weight loss	126 (4.4%)	36 (7.2%)	90 (3.8%)	0.001

¹Assessed during the 12-month baseline period before the index date (4/1/2020); AIDS: acquired immunodeficiency syndrome; COVID: coronavirus disease; HIV: human immunodeficiency virus; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus